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The relationship between diabetes mellitus and heart disease is widely documented, with heart 
disease being the main cause of mortality in diabetic patients. Diabetes impairs the autonomic 
nervous system, leading to an imbalance between parasympathetic and sympathetic nervous 
output. Alterations in autonomic cardiac balance in diabetes may lead to fatal arrhythmias and 
impairments in contractility. Calcium/calmodulin-dependent protein kinase II (CaMKII) is a 
key regulator of cardiac contractility and is overactive in diabetes mellitus. CaMKII inhibition 
in diabetic models reduces both arrhythmogenic events and impaired cardiac contractility. Our 
laboratory has previously implicated CaMKII in the α-adrenergic cascade, although the role of 
both in diabetes-induced cardiac dysfunction is unclear. I hypothesised that CaMKII and the α-
adrenergic system are dysregulated in diabetes, which may underlie arrhythmogenesis and 
impaired contractility in diabetic patients. 
Trabeculae from human right atrial appendage tissue were superfused with either methoxamine 
(an α-adrenergic agonist) or KN93 (a CaMKII inhibitor) followed by the two in conjunction. 
Changes in contractility and spontaneous contractions in the atrial samples were measured. 
CaMKII inhibition with KN93 consistently reduced the contractile function of the non-diabetic 
trabeculae and prevented a positive inotropic effect from methoxamine administration. This 
was consistent with previous work implicating CaMKII in the α-adrenergic cascade in mouse 
models. All samples showed no increase in arrhythmic events with methoxamine 
administration. We did not observe significant differences in the contractile response of diabetic 
and non-diabetic tissue with methoxamine administration.  Diabetic tissue responded with an 
increase in developed force with addition of methoxamine and KN93, as opposed to non-
diabetic tissue which showed a decrease in developed force. An equal proportion of both 
diabetic and non-diabetic samples showed a significant negative inotropic effect in response to 
methoxamine when compared with positive responders to the drug. The inotropic response to 
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methoxamine seems to correlate with the duration of diabetes in diabetic patients, although 
some other factor may be influencing the non-diabetic negative inotropic response. 
This study is the first to implicate CaMKII in the α-adrenergic cascade in human cardiac tissue. 
The response to α-adrenergic stimulation seems to be dependent on a factor independent to 
diabetes, as similar proportions of negative responders to the drug were present in both non-
diabetic and diabetic populations. The correlation of the blunted inotropic response to 
methoxamine with diabetes duration may be impacted by progressive denervation occurring in 
late stage diabetics, resulting in impaired responses to α-adrenergic agonists. The implication 
of CaMKII in the α-adrenergic cascade contraindicates the use of α-adrenergic agonists in 
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Chapter 1: Introduction 
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1.1 Diabetes Mellitus 
1.1.1 Types of Diabetes 
Diabetes Mellitus (DM) is classified into two distinct types (American Diabetes Association, 
2014). In brief, type 1 DM (T1DM) involves an autoimmune reaction to the β-islet cells of the 
pancreas, resulting in either a complete, or major loss of endogenous insulin production. Type 
2 DM (T2DM) is typical of a resistance to the action of insulin, often due to environmental 
factors such as diet and exercise. Gestational DM is another distinct form of DM occurring 
during pregnancy, although this will not be covered in this thesis. T2DM makes up the majority 
of DM cases, accounting for 91.2% of cases in a population of US adults in 2016/17, while 
T1DM only accounted for 5.6% of cases (Xu et al., 2018).  
1.1.2 Prevalence of Diabetes Mellitus 
The prevalence of DM worldwide is increasing rapidly, with figures showing a four-fold 
increase from 108 million cases in 1980 to an estimated 422 million cases in 2014 (World 
Health Organisation, 2016). This increase is not solely due to rising populations, as there has 
been an increase in global DM prevalence among adults from 4.7% to 8.5% in the same period 
(World Health Organisation, 2016). These figures outpace previous projections, estimating only 
328 million cases worldwide by 2030 (Mathers & Loncar, 2006), with current projections 
estimating a rise to 642 million cases by 2040 (Ogurtsova et al., 2017). Similar to global 
prevalence, 6.5% of New Zealand adults were estimated to have T2DM in the years 2017/18, 
an estimated 211,000 individuals (Ministry of Health, 2019). Furthermore, 32.2% of New 
Zealand adults were classified as obese within this time period, with obesity being a leading 
risk factor in the development of T2DM (Ministry of Health, 2019). 
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1.1.3 Mortality of Diabetes Mellitus 
Along with the rapidly rising global prevalence of DM, a substantial mortality is associated 
with the disease. The International Diabetes Federation estimated that DM was responsible for 
12.8% of global all-cause mortality among adults in 2015 (Ogurtsova et al., 2017). These 
epidemiological studies show the substantial impact that DM has on the modern world, which 
is only expected to grow as disease prevalence rapidly increases. Preventing the root cause of 
the problem by changing environmental and lifestyle factors presents an obvious target with 
which to combat the DM epidemic. Changing these environmental and lifestyle factors will not 
alleviate the acute effect of diabetes on public health, such as the substantial impact DM has on 
cardiovascular factors. 
1.2 Diabetes Mellitus and Heart Disease 
The association between DM and heart disease is well documented, with the landmark 
Framingham Heart Study providing epidemiological evidence linking the two conditions. In a 
16-year follow up of the Framingham study, Garcia et al. (1974) found a significantly increased 
mortality from cardiovascular disease (CVD) in diabetics compared to non-diabetics within the 
same population. Other studies have reported similar results (Kessler, 1971). Heart disease has 
been found to account for a majority of recorded causes of death among diabetic patients, 
accounting for 69.5% of deaths in one study (Gu et al., 1998). Diabetes has been associated 
with structural cardiac pathologies such as left ventricular remodelling and cardiac steatosis 
(Levelt et al., 2016). Many pathologies observed in models of DM result in phenotypes 
associated with heart failure, such as impaired cardiac contractility and increased arrhythmia, 
which will be explored further in this thesis. 
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1.2.1 Diabetes and Cardiac Contractility 
Cardiac contractility is a measurement representing the ability of the heart to contract. That is, 
the force and velocity at which myofilaments contract within cardiomyocytes. Factors which 
increase cardiac contractility are said to have a positive inotropic effect (PIE), while factors 
which decrease cardiac contractility are said to have a negative inotropic effect (NIE). Cardiac 
contractility can be influenced by activity of the nervous system, hormones, drugs, heart rate 
and various metabolic factors. Activation of the sympathetic nervous system generally results 
in a PIE in the heart, whilst activation of the parasympathetic nervous system generally results 
in a NIE. Contractility can be measured by determining developed force over a contraction, 
from the maximum developed force to the minimum developed force. 
Both animal and human diabetic cardiomyocytes have been observed to have decreased 
contractility (Bening et al., 2018; Daniels et al., 2018), suggesting the impact that DM has on 
contractile elements within cardiac tissue. The cause for this contractile dysfunction may be 
multifactorial, however, various DM models have highlighted impairments in calcium handling 
(Guner et al., 2004; Pereira et al., 2006; Shi et al., 2013; Cheng et al., 2016; Thapa et al., 2018). 
Diabetic denervation may also upset the sympathetic and parasympathetic innervation to the 
heart, resulting in impaired contractility. Furthermore, many metabolic pathways are altered in 
the diabetic state. One in particular is  the increased cardiac utilisation of fatty acids which 
impairs cardiac efficiency (Bugger & Abel, 2014). Moreover, oxidative stress production is 
increased by altered metabolic pathways in DM (Brownlee, 2001). The increased levels of 
oxidative stress seen in DM (Rehman & Akash, 2017) have been reported to affect calcium 
handling (Cheng et al., 2016) and diabetic denervation (Low & Nickander, 1991), further 
contributing to diabetic pathologies. Both metabolic imbalances and imbalances in the 
parasympathetic and sympathetic balance in diabetic heart disease can interfere with normal 
excitation contraction coupling present in the heart, leading to arrhythmogenesis. 
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1.2.2 Diabetes Mellitus and Arrhythmia 
Diabetes is well known to be associated with an increased risk of arrhythmogenesis (Benjamin 
et al., 1994; Movahed et al., 2005). Aubin et al. (2010) found that only 8 weeks of a high fat 
diet in rat models was necessary to induce an arrhythmogenic phenotype, this occurring before 
the animals became overtly diabetic. Aubin et al. (2010) suggested that cardiac sympathetic 
hyperinnervation may be responsible for this phenotype. Sympathetic hyperinnervation is a 
well described clinical aspect of cardiovascular autonomic neuropathy (CAN), which is 
commonly observed in DM (Pop-Busui, 2012). It has been suggested that a heterogeneous 
activation of α1-adrenergic receptors across the heart may result in arrhythmia, due to differing 
repolarisation times throughout the cardiac tissue (Kurz et al., 1991). Senges et al. (1980) noted 
that diabetic rabbit atria present with inhomogeneity of atrial conduction and atrioventricular 
(AV) node blockage, in which signal conduction between the atria and ventricles is impaired. 
This heterogeneous atrial conduction in diabetic hearts could lead to arrhythmia via the 
mechanism described by Kurz et al. (1991). 
1.2.3 Autonomic Imbalance in Diabetes 
Diabetic patients are often affected by an imbalance in autonomic nervous tone, presenting as 
nocturnal sympathetic predominance (Spallone et al., 1993), and sympathetic over activation 
(Imam et al., 2016). Atrial conduction is also affected in DM, which may be a consequence of 
this impaired autonomic balance between parasympathetic and sympathetic nervous systems. 
Diabetic rabbit atria present with slower sinus rate, inhomogeneity of atrial conduction and AV 
node blockage (Senges et al., 1980). Diabetic rat atria also show a significantly lower sensitivity 
to acetylcholine administration (Kofo-Abayomi & Lucas, 1988). Alterations in cardiac 
autonomic balance are likely to contribute to arrhythmogenesis in DM, due to altering the 
conduction mechanisms within the cardiac tissue. These alterations in cardiac autonomic 
balance often manifest as impairments in adrenergic receptor function, affecting normal cardiac 
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function in diabetic individuals. The predominant types of cardiac adrenergic receptors are the 
β-adrenergic receptors (for review see Wallukat (2002)), although this thesis will focus on 
cardiac α-adrenergic receptors. 
1.3 α-Adrenergic Receptors 
α1-Adrenergic receptor stimulation 
typically leads to heightened intracellular 
calcium via increased phosphoinositol 
hydrolysis (Motulsky & Insel, 1982). 
Phosphoinositol undergoes hydrolysis to 
form inositol triphosphate, increasing 
calcium release and resulting in a PIE in the 
heart (Skomedal et al., 1982; Otani et al., 
1988; Xiang & McNeill, 1991). The 
hydrolysis of phosphoinositol also produces 
diacylglycerol, which activates protein 
kinase C. A schematic of this signal 
transduction pathway is shown in Figure 
1.1. A PIE from α-adrenergic stimulation 
has been demonstrated in human atria, 
operating within physiological frequencies 
at 1 Hz of stimulation (Schümann et al., 1978).  
1.3.1 α-Adrenergic Receptor Impairment in Diabetes 
α1-adrenergic receptor (α1-AR) agonists (such as methoxamine/MTX) are known to produce a 
PIE in the heart in physiological conditions (Reid, 1986). However, this response is thought to 
differ in DM. In a novel study by Heyliger et al. (1982), changes to cardiac α-ARs and β-ARs 
Figure 1.1: Typical α1-adrenergic signalling pathway. 
Typical α-adrenergic signal transduction pathway. An α-
agonist interacts with a G-protein coupled receptor on the 
cell membrane. The Gαq subunit activates phospholipase C 
(PLC) which breaks down phosphoinositol (PIP2) into 
inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 
increases intracellular Ca2+ release, and DAG activates 
protein kinase C (PKC). Veitch 2019, original work. 
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were examined in streptozotocin (STZ) induced diabetic rat models. Responses to both MTX 
administration and isoproterenol (a β-AR agonist) were reduced in diabetic samples compared 
to non-diabetic samples, which was suggested to be due to an observed decrease in both α and 
β-AR density (Heyliger et al., 1982). The impaired β-AR response has also been observed in 
models of heart failure, which was suggested to be due to increased catecholamine levels 
downregulating the receptors (Bristow et al., 1982). Various studies following Heyliger et al. 
(1982) support this finding of impaired α1-ARs (Williams et al., 1983; Latifpour & McNeill, 
1984; Tanaka et al., 1992). Williams et al. (1983) observed downregulation of both α-ARs and 
β-ARs, suggesting this may be due to increased catecholamines (as also suggested by Bristow 
et al. (1982) in a heart failure model) or glycosylation of the receptors. In long-term 
experimental DM, a progressive decrease in α1-AR density has been observed (Latifpour & 
McNeill, 1984). Interestingly, Tanaka et al. (1992) note that this decrease in cell surface α1-AR 
concentration is reversed by chronic insulin administration. 
1.3.2 α-Adrenergic Receptor Sensitisation in Diabetes 
There is however a substantial body of evidence contradicting Heyliger et al. (1982), and 
instead showing an enhanced response to α-agonists or upregulation of α1-ARs in experimental 
DM. A heightened contractile response to α1-AR stimulation has been observed (White & 
Carrier, 1988; Xiang & McNeill, 1991; Beenen et al., 1996), which has been suggested to 
compensate for the impaired β-AR response (Lafci-Erol et al., 1994). Furthermore, the response 
to phenylephrine (an α-agonist) has also been shown to increase in DM (Jackson et al., 1986; 
Ha et al., 1999). This further supports findings suggesting the α1-AR response is sensitised in 
DM, as the PIE of phenylephrine has been suggested to be entirely mediated by the α1A-AR 
subtype (Nagashima et al., 1997). 
Despite many investigators agreeing that the PIE of α-AR stimulation increases in DM, conflict 
persists over whether α-ARs are overexpressed (Huisamen et al., 2004), or have decreased 
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expression while becoming sensitised to α-AR stimulation (Wald et al., 1988; Kamata et al., 
1997). Following from their previous study, Kamata et al. (2006) again showed an increased 
response to α1-AR stimulation by MTX at 10 weeks of DM, but that α1-AR mRNA expression 
was upregulated in 10-week diabetic models, which represents late-stage DM in the rat.  
1.3.3 α-Adrenergic Receptors in Diabetic Pathologies 
Changes in α1-ARs have been observed in various other diabetic pathologies. Sellke et al. 
(2018) observed that differences in the effects of phenylephrine between diabetic and non-
diabetic patients were only obvious following cardiac/cardiopulmonary surgery. STZ-induced 
DM has been observed to cause a significant decrease in prostate α1-AR density (Nishi et al., 
1998), while the renal α1D-ARs are significantly upregulated in diabetics, and may play a role 
in diabetic renal pathology (Zhao et al., 2014). Furthermore, α1A-AR antagonists ameliorated 
impaired bladder function and loss of sensory nerves in diabetic rats (Yonekubo et al., 2017). 
The finding that α1A-ARs may be involved in sensory nerve loss in Yonekubo’s study is 
intriguing and may implicate α1A-ARs in diabetic autonomic neuropathy. 
1.3.4 α-Adrenergic Receptors in Diabetes Progression 
α2-AR have been implicated in DM progression, with stimulation of these receptors being found 
to prevent alloxan-induced experimental DM (Nakadate et al., 1983). In human subjects, 
overexpression of α2A receptors by the ADRA2A gene is associated with an increased risk of 
T2DM (Rosengren et al., 2010). A general blockade of α-ARs with phentolamine has also been 
shown to increase levels of basal insulin in human diabetics, and partially restore the insulin 
response to IV glucose administration (Robertson et al., 1976). The difference between the 
findings of these studies may be due to the use of alloxan-induced DM compared to clinical 
human DM, as human pancreatic β-cells may be resistant to alloxan (Eizirik et al., 1994). 
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1.3.5 α-Adrenergic Receptors in Arrhythmia 
Sheridan et al. (1980) noted that the α-adrenergic system may be important in dysrhythmia 
following ischaemia-reperfusion injury. α-AR antagonists prevented arrhythmogenesis during 
reperfusion, suggesting a key role for α-AR in arrhythmogenesis following myocardial injury. 
Kurz et al. (1991) summarises various arrhythmogenic effects of α-agonists and suggests that 
ischaemia results in an enhanced response to α-AR stimulation. α1A-ARs are known to still be 
functional following heart failure in humans, with selective α1A-AR agonists producing a PIE 
(Janssen et al., 2018). It is possible that as these receptors maintain function even after heart 
failure, they could provide a mechanism for arrhythmogenesis within the diabetic heart. 
1.4 Novel Therapies for Diabetes Mellitus 
Therapies for DM often focus on glycaemic control, aiming to reduce blood glucose levels of 
these patients in order to alleviate the resultant symptoms. Hyperglycaemia is well 
characterized to be a major player in the pathogenesis of diabetic complications such as 
neurotoxicity (Tomlinson & Gardiner, 2008) and micro/macrovascular complications 
(Brownlee, 2001). However, excessive glycaemic control may be a risk factor for arrhythmia, 
as hypoglycaemic diabetic patients show a higher risk of arrhythmia than euglycaemic or 
hyperglycaemic patients (Chow et al., 2014). Care should be taken when diabetics are put on 
glycaemic control regimes, as this could exacerbate the existing risk for arrhythmogenesis in 
these patients. DM often occurs alongside hypertension (Tatsumi & Ohkubo, 2017), of which 
β-blockers are commonly prescribed as treatment for hypertension. Conventional β-blockers 
may be a risk factor for DM, with the risk of DM being greater in diabetic patients taking β-
blockers compared to those taking no medication (Gress et al., 2000). Thus, novel therapies 
need to be developed in order to combat the risk of DM-induced arrhythmogenic events, with 
molecular targets emerging as promising treatment opportunities.  
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1.5 CaMKII 
1.5.1 CaMKII Structure and Activation 
Calcium and calmodulin-dependent protein kinase II (CaMKII) is a 12-subunit protein kinase, 
which has various physiological roles in phosphorylating target proteins, and involvement in 
the cardiac fight/flight response (Wu et al., 2009). Each subunit consists of a regulatory domain, 
a catalytic domain and an association domain (Rosenberg et al., 2005). Under basal conditions 
the regulatory domain auto-inhibits the catalytic domain of the enzyme, preventing it from 
phosphorylating target proteins (Rosenberg et al., 2005). In conditions of high intracellular 
Ca2+, calmodulin (CaM) binds to the regulatory domain, resulting in dissociation of the 
regulatory domain from the catalytic domain and allowing for substrate binding (Rosenberg et 
al., 2005). A schematic diagram of this activation is shown in Figure 1.2. Modification of the 
regulatory domain by various post-translational modifications is also able to result in 
autonomous activation of the enzyme. 
Figure 1.2: Schematic of CaMKII activation. Red: association domain; Green: regulatory domain; Blue: catalytic 
domain; Yellow: calcium/calmodulin. A: catalytic domains are bound to regulatory domains, CaMKII is unable to 
bind to substrates. B: calcium/calmodulin are bound to the regulatory domain, releasing the catalytic domain and 
allowing CaMKII to phosphorylate target proteins. Veitch 2019, original work. 
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1.5.2 Autonomous Activation of CaMKII 
Under normal physiological conditions, a drop in Ca2+/CaM concentrations will result in the 
catalytic domain of CaMKII re-associating with the regulatory domain, preventing kinase 
activity (Lai et al., 1986). Activated catalytic domains are able to autophosphorylate other 
regulatory domains at the Thr286 site (Rosenberg et al., 2005), allowing the enzyme to stay 
active even without the presence of Ca2+/CaM (Lai et al., 1986). Other sites on the regulatory 
domain are known to be modified by various substrates, leading to autonomous activation akin 
to physiological autophosphorylation of the enzyme. Autonomously activated CaMKII can be 
pathological, such as in DM, which will be further discussed below. 
1.5.3 CaMKII and Cardiac Pathology 
CaMKII has been implicated in various cardiac pathologies, with inhibition of the enzyme 
alleviating the impaired contractility seen in both T2DM (Daniels et al., 2018) and heart failure 
(Sossalla et al., 2010). CaMKII is involved in endothelial cell apoptosis (Timmins et al., 2009), 
and preventing activation of CaMKII following myocardial infarction reduces the risk of 
sudden death in diabetic mice (Luo et al., 2013). 
1.5.4 CaMKII Activation in Diabetes 
CaMKII may be activated by a variety of pathways and mechanisms in DM. In hyperglycaemic 
conditions, post-translational modification of proteins by O-GlcNAcylation is increased as 
glucose is converted into the substrate for O-GlcNAcylation (UDP-N-Acetylglucosamine) via 
the hexosamine biosynthesis pathway (Yang & Qian, 2017). O-GlcNAcylation of CaMKII has 
been observed in both hyperglycaemic animal models and diabetic patients, leading to 
autonomous activity of the enzyme (Erickson et al., 2013). Oxidation of CaMKII at M281/282 
is also known to result in autonomous activity of the enzyme (Erickson et al., 2008), with levels 
of oxidative stress and reactive oxygen species known to increase in hyperglycaemic conditions 
such as DM (Cheng et al., 2016).  
12 
1.5.5 CaMKII and Adrenergic Stimulation 
The involvement of CaMKII in the physiological fight/flight response to β-AR stimulation (Wu 
et al., 2009) shows the regulation of CaMKII by the β-AR cascade. CaMKII is also involved in 
β1AR-mediated apoptosis (Zhu et al., 2003), and inhibiting CaMKII prevents pathological β-
AR signalling in structural heart disease (Zhang et al., 2005). Inhibition of the enzyme has been 
shown to prevent isoproterenol-induced arrhythmias (Feng et al., 2017), implicating CaMKII 
in pathological arrhythmogenesis and the β-AR cascade. Khan (2019) found that α-AR 
stimulation had no functional effects in CaMKII knockout mouse models, implicating the role 
of CaMKII in the downstream effects α-AR stimulation has on the heart. 
1.5.6 CaMKII and Arrhythmia 
CaMKII is well characterised in its involvement with arrhythmia, with inhibition of the enzyme 
reducing a CaMKII mediated increase in late sodium current, preventing arrhythmogenesis (Ma 
et al., 2012). Increased levels of the oxidised form of the enzyme are associated with sinus node 
dysfunction in mouse models, with sinus node dysfunction strongly associated with sudden 
cardiac death (Swaminathan et al., 2011). Along with observing O-GlcNAcylation of the 
enzyme during diabetic hyperglycaemia, Erickson et al. (2013) noted that modified CaMKII 
was involved in arrhythmogenesis. Inhibiting CaMKII and O-GlcNAcylation was able to 
prevent Ca2+ sparks, and reduce arrhythmia susceptibility in a caffeine/dobutamine challenge 
(Erickson et al., 2013). Blocking CaMKII activation improves abnormalities seen in high-fat 
diet mice hearts, such as increased arrhythmia susceptibility and alterations in expression of 
Ca2+ handling proteins (Zhong et al., 2017). CaMKII may also be involved in arrhythmogenesis 
following ischaemia-reperfusion injury (Howard et al., 2018). 
1.5.7 RyR2, CaMKII and Arrhythmogenesis 
One mechanism by which CaMKII is well known to affect arrhythmia is by its modification of 
the ryanodine receptor 2 (RyR2), a Ca2+ channel located on the sarcoplasmic reticulum. 
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CaMKII phosphorylates RyR2 resulting in dissociation of the stabilizing protein FKBP12.6, 
leading to increased intracellular calcium leak (Wehrens et al., 2004). This modification of 
RyR2 by CaMKII increases Ca2+ leak through RyR2, resulting in increased Ca2+ sparks and 
arrhythmogenesis (van Oort et al., 2010; Ather et al., 2013; Grimm et al., 2015; Mazzocchi et 
al., 2016). CaMKII modification of RyR2 may also be key in pathologies resulting from chronic 
β-AR stimulation (Grimm et al., 2015). Zhong et al. (2017) noted in their study that high fat 
diet mouse hearts expressed increased phosphorylation of RyR2, further implicating the role of 
DM and hyperlipidaemia in arrhythmogenesis. 
1.5.8 CaMKII and the α-Adrenergic Cascade 
CaMKII and α1-ARs are both well known to be altered during DM and may contribute to 
arrhythmogenesis by the aforementioned mechanisms. The finding that CaMKII is involved in 
mediating the effects of α-AR stimulation by Khan (2019) is intriguing, which may implicate 
α-AR stimulation and CaMKII in arrhythmogenesis and contractile dysfunction in DM. The 
aforementioned changes observed in α-AR density in DM have not been examined in human 
cardiac samples, which could provide an insight into the functional changes in the heart in DM. 
1.6 Aims and Hypotheses 
This project aimed to elucidate the potential changes of α-adrenergic stimulation on contractile 
parameters and arrhythmogenic events in the diabetic heart. This project also evaluated the 
potential for a therapeutic agent to reduce arrhythmogenesis in diabetic human hearts by 
targeting α-ARs. The project aimed to determine the role CaMKII has in α-adrenergic 
stimulation in diabetic human hearts, and how this may influence arrhythmia. This built on 
previous work by Khan (2019) in our laboratory, which implicated CaMKII in the α-AR 
cascade. 
I hypothesised that the contractile response to MTX administration would be reduced in diabetic 
samples compared to non-diabetic samples and that MTX administration would result in 
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arrhythmogenesis in the tissue. As CaMKII is associated with increased levels of calcium 
cycling and is overactive in diabetic patients, I originally hypothesised that inhibition of 
CaMKII would decrease contractility in diabetic samples to a greater extent than non-diabetic 

























Use of human tissue and collection of samples from human patients was approved by the 
Human and Disability Ethics Committee of New Zealand. Patients undergoing surgery 
provided informed consent for the use of their tissue through the Heart Otago study. 
2.2 Cardiac Tissue 
2.2.1 Surgery 
Surgeries included coronary artery bypass graft (CABG), mitral valve replacement (MVR), 
aortic valve replacement (AVR) and aortic replacement surgery. The Right Atrial Appendage 
(RAA) was removed from these patients as part of normal surgical procedure and immersed in 
Krebs Henseleit Buffer (KHB) with 25mM of BDM (2,3-Butanedione monoxime, B0753, 
Sigma-Aldrich, U.S.A). BDM was used to inhibit metabolic activity within the sample before 
experimentation. The KHB used had a composition outlined in Table 2.1. This solution was 
bubbled with carbogen (95% O2, 5% CO2) prior to collection of the tissue, to oxygenate the 
sample during transport to the lab. 
2.2.2 Trabeculae Extraction 
RAA samples were transported to the lab in the KHB + BDM solution on ice and dissected into 
thirds in the lab. One of these thirds was placed under a stereomicroscope (World Precision 
Instruments, U.S.A) and a thin, non-branching, linear trabecula was isolated from the sample. 
Small amounts of tissue were also dissected on either end of the trabeculae, to aid in mounting. 
The RAA sample was bathed in fresh KHB + BDM solution which was bubbled with carbogen 
throughout the dissection. 
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Cross-sectional area (CSA) of the dissected trabeculae was measured to allow calculation of 
force produced per mm2 of each trabeculae sample. The CSA of each trabeculae was measured 
by the following equation: 
𝐶𝑆𝐴 = 𝑤 2 ×
𝑑
2 × 𝜋 
Where w = width and d = diameter of the sample measured through 2x magnification of a 
stereomicroscope (World Precision Instruments, U.S.A). Measured width of the sample was 
taken at the smallest observed width. 
Dissection of the trabeculae was performed mainly by Hamish Aitken-Buck from the Lamberts 
Lab, with some samples later in the research project being dissected by myself. This was done 
to minimise waste of the human tissue samples when I was not experienced with the dissection 
procedure. No significant alterations to contractile parameters were observed between 
trabeculae isolated by Hamish and myself. 
2.3 Experimental Setup 
The experimental setup used for this project was of a similar setup as described in Lamberts et 
al. (2014) and the rat trabeculae experiments in the Daniels et al. (2018) study. 
2.3.1 Buffer Solution 
The superfusate used in the experimental protocols consisted of KHB, the composition of which 
is shown in Table 2.1. 150 µL of 1M CaCl2 was added to 100mL of KHB to result in a final 
concentration of 1.5 mM Ca2+ in the buffer solution. Calcium was added to the superfusate on 
the day of experiments to extend the shelf-life of the KHB. 
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Table 2.1: Composition of KHB used in trabeculae experiments. 
Components Concentration (mM) Molar Mass (g.mol-1) 
NaCl 118.50 58.44 
KCl 4.50 74.55 
MgCl26H2O 1.00 203.30 
NaH2PO4H2O 0.33 137.99 
NaHCO3 25.00 84.01 
Glucose 11.00 180.16 
 
2.3.2 Water Bath and Tubing 
Measuring cylinders with 100ml of KHB were warmed in a water bath (LAUDA-Brinkmann, 
LP, U.S.A) at 37 °C for the duration of the experiments. This solution was bubbled with 
carbogen to oxygenate the tissue. Peristaltic pumps (World Precision Instruments, U.S.A) 
pumped the superfusate through a heat transfer coil in a double-jacketed system connected to 
the 37 °C muscle bath, reducing heat loss from the buffer on the way to the tissue bath. A 
syringe connected by a three-way valve to the tubing system contained a small amount of buffer 
solution and air, positioned before the superfusate entered the tissue bath. This had action akin 
to the windkessel effect of the aorta, reducing pulsatile flow. This also allowed for air emboli 
to be taken out of the system before entering the tissue bath. Following passage through the 
tissue bath, the superfusate passed through a 0.45 µm filter before being recirculated into the 
solution of KHB. A schematic diagram of the water bath and tubing is shown in Figure 2.1. 
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Figure 2.1: Schematic diagram of experimental setup. A: Carbogen cylinder containing 95% O2, 5% CO2 which 
aerated the tissue bath throughout the procedure. B: Water bath maintained at 37°C. C: Measuring cylinder with 
100mL of KHB + 1.5mM Ca2+, bubbled with carbogen. D: Tubing carrying superfusate to and from the tissue 
bath. Flow direction is indicated with arrows. E: Peristaltic pumps. F: Heat transfer coil surrounding intake tube, 
maintaining 37°C temperature throughout the tubing. G: Syringe attached to intake tubing via 3-way valve, acting 
as a windkessel to reduce pulsatile flow. H: Tissue bath containing trabecula suspended by hooks, attached to a 
force transducer (I) and a micromanipulator (J). K: Force measurements from the force transducer are graphed 
on LabChart. Representative contractions at 1Hz are shown. L: 0.45 µm Filter to remove toxic metabolites 
produced by tissue, before superfusate is recirculated through the experimental setup. Veitch 2019, original work. 
2.3.3 Tissue Bath 
The trabeculae sample was attached on hooks, one attached to a micromanipulator allowing for 
stretching of the muscle. The other hook was attached to a force transducer, signal conditioning 
amplifier system (World Precision Instruments, U.S.A) and integration software (LabChart 8 
Software, AD Instruments, NZ) allowing for measurements of contractile parameters. The 
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custom-built tissue bath circulated superfusate past the trabecula sample throughout the 
experiment. 
Horizontal paired platinum electrodes located in the walls of the tissue bath allowed for delivery 
of an external electrical stimulus to the sample. Electrodes were connected to a Grass SD9F 
stimulator (Grass Instruments, U.S.A). Biphasic 1 Hz stimulation at 100 volts with minimal 
delay and a 5-millisecond duration was used throughout the experimental protocol. 
2.3.4 Contractile Parameters 
Maximum force, minimum force and maximum to minimum force (mN/mm2) were recorded 
with the Blood Pressure module in LabChart 8 (AD Instruments, NZ) to allow determination 
of the developed force of trabecula over one contraction. Developed force was measured by 
calculating the difference between maximum and minimum force over one contraction.  
Maximum dF/dt and minimum dF/dt (mN/mm2/s) were recorded with LabChart to measure the 
rate of contraction (max dF/dt) and rate of relaxation (min dF/dt) of the muscle samples. Max 
dF/dt was recorded at the fastest velocity of myocardial contraction, to produce a measurement 
of the rate of contraction of the trabeculae. Min dF/dt was recorded at the fastest velocity of 
relaxation, to produce a measurement of the rate of relaxation of the trabeculae. A representative 
trace of the contractile parameters measured is shown in Figure 2.2. 
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Figure 2.2: Representative trace of contractile parameters. LabChart 8 (AD Instruments, N.Z) showing recorded 
contractile parameters over one contraction using the LabChart 8 Blood Pressure module. Fdev (developed force), 
Max dF/dt, max pressure, min dF/dt and min pressure are shown. Parameters analysed in the results are shown 
with a red line over the trace of the contraction. Image modified from LabChart 8 software. 
2.4 Experimental Protocol 
2.4.1 Setup 
Dissected trabeculae were attached to the force transducer and micromanipulator, then 
immersed in the muscle bath containing KHB + 1.5mM Ca2+. 
Trabeculae were stretched to an optimal length by progressive stretches from the 
micromanipulator. Optimal length was determined by the point at which produced force from 
the muscle did not increase with further stretching, indicating optimal overlap of sarcomeres 
within the cardiomyocytes. 
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2.4.2 Spontaneous Contractions 
To test for spontaneous contractions, electrical stimulation of the trabeculae was ceased for a 
period of 60 seconds, and any aberrant waveforms were observed and recorded on the LabChart 
software. A representative image of observed spontaneous contractions is shown in Figure 2.3. 
 
Figure 2.3: A representative image of spontaneous contractions. Spontaneous contractions seen following 
cessation of stimulation at the red line labelled STOP. Return to a normal stimulation frequency of 1Hz is seen at 
the red line labelled START. Spontaneous contractions in this period occurred at a frequency of ~0.4Hz. 
2.4.3 Protocol 
Baseline recordings from the muscle were performed once the muscle had reached optimal 
length and had reached a stable baseline force. A test for spontaneous contractions was 
performed at baseline following the muscle reaching a stable baseline force. 
Following baseline recording, 100µL of a 10-2 M MTX stock solution (Methoxamine 
Hydrochloride, M6524, Sigma-Aldrich, U.S.A) was added to the 100mL KHB + Ca2+ solution, 
to produce a concentration of 10-5 M MTX within the muscle bath. This concentration was 
determined based on previous dose-response curves performed by Khan (2019) in mouse 
models, and my own preliminary dose-response experiments on human trabeculae. MTX was 
washed through the muscle for a 30-minute period before performing another test for 
spontaneous contractions. 
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The tissue bath and muscle were washed out with a new solution of KHB + 1.5mM Ca2+ for 30 
minutes, and another test for spontaneous contractions was performed. During this time the 
solution was not recirculated for 20 minutes, allowing the new KHB superfusate to wash out 
any remaining MTX in the tissue sample. 
7.5µL of a 26mM stock solution of KN93 suspended in 100% DMSO (KN-93 hydrochloride, 
B1306, APExBIO Technology LLC, U.S.A) was added to the 100mL KHB + Ca2+ + MTX 
solution, to produce a concentration of 1.95µM of KN93 within the muscle bath. This solution 
was then circulated through the muscle bath for 30 minutes, followed by another test for 
spontaneous contractions. A schematic of the experimental protocol is shown in Figure 2.4. 
 
Figure 2.4: Schematic of experimental protocol. Following each phase of the experimental protocol (phase 
indicated by arrow) a test for spontaneous contractions was performed. 
To act as a control for KN93, the inactive analogue KN92 (KN-92 hydrochloride, A3530, 
APExBIO Technology LLC, U.S.A) was used for control experiments. 975μL of a 200µM 
stock solution of KN92 suspended in 100% DMSO was added to the 100mL KHB + Ca2+ + 
MTX solution, to produce a concentration of 1.95μM of KN92 within the muscle bath. This 
superfusate was then circulated through the muscle bath for 30 minutes, followed by another 
test for spontaneous contractions. 
2.4.4 Tissue Storage 
Following the final phase of the experimental protocol, the trabeculae sample was immediately 
snap frozen in liquid nitrogen and stored in a -80 °C freezer. This allowed for future analysis of 
the tissue by immunoblot or other methods. 
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2.5 Data Analysis 
2.5.1 Exclusion Criteria 
Patient data was obtained through the Heart Otago study and included an extensive list of 
parameters. These included anthropometric, haemodynamic, pharmacological and biochemical 
information for each patient. Patients with an ejection fraction <45% were excluded from this 
study. If the developed force of a sample degraded at a rate greater than 15% of baseline 
developed force over an hour without drug addition, it was excluded from the final analysis. 
2.5.2 Controls 
Recordings at baseline were performed to act as a control before addition of MTX to the 
superfusate, allowing comparison between baseline contractility and contractility with MTX 
superfusion. To control for KN93, the inactive analogue KN92 was added in place of KN93 to 
the tissue sample in control experiments. Time controls were performed by adding KN93/KN92 
to the muscle bath following baseline recordings, followed by a wash phase and addition of 
MTX to the superfusate. 
2.5.3 Analysis 
Raw data recorded using the Blood Pressure module on LabChart 8 software was transformed 
in Microsoft Excel 2018 (Microsoft Corporation, U.S.A), to produce both absolute values and 
fold changes of contractile parameters. This data was further analysed in GraphPad Prism 8 
(GraphPad Software Inc, U.S.A) for statistical analysis and creation of graphs. 
2.5.4 Statistical Tests 
Statistical tests were performed using GraphPad Prism 8, with a p-value of <0.05 considered 
significant. For comparisons between parameters of diabetic and non-diabetic samples, 
repeated measure two-way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple 
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comparisons tests were performed. For correlation data between diabetic characteristics and the 




















Chapter 3: Results 
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3.1 Baseline Characteristics  
Relevant patient characteristics were similar between both the non-diabetic and diabetic groups, 
with no significant differences in characteristics such as age, muscle CSA and MABP as shown 
in Table 3.1. Diabetic patients had significantly higher levels of HbA1C (48.3 ± 2.47) compared 
to non-diabetics (35.2 ± 1.08), but not significantly different levels of blood glucose. Diabetic 
patients had significantly higher BMI (31.5 ± 1.31) compared to non-diabetics (26.3 ± 1.37). 
Patients had diabetes for an average duration of 9.83 ± 1.28 years. 4/11 non-diabetic patients 
were taking β-blocker medication, compared to 3/6 diabetic patients. 4/11 non-diabetic patients 
were on current ACE inhibitor medication, compared to 5/6 diabetic patients. E velocity 
represents blood flow from the left ventricle in early diastole, while A velocity represents blood 
flow from the left ventricle in late diastole. E velocity, A velocity, the E/A ratio and ejection 
fractions were not significantly different between non-diabetic and diabetic patients, suggesting 











Table 3.1: Baseline characteristics of diabetic and non-diabetic patients. Data presented as mean ± SEM. 
Statistical difference between diabetic (n=6) and non-diabetic groups (n=11) calculated with an unpaired, two-
tailed, students t-test. BMI = Body Mass Index, HbA1C = glycated haemoglobin levels, MABP = Mean Arterial 
Blood Pressure. 
Parameter Non-Diabetic Diabetic P-value 
Age (years) 67.2 ± 1.97 72 ± 3.20 0.195 
Sex 10 M, 1 F 4 M, 2 F n/a 
Muscle CSA (mm2) 0.592 ± 0.0545 0.493 ± 0.0945 0.342 
BMI 26.3 ± 1.37 31.5 ± 1.31 0.0275 
HbA1C (mmol/mol) 35.2 ± 1.08 48.3 ± 2.47 <0.001 
Glucose (mmol/L) 5.83 ± 0.676 7.27 ± 0.867 0.239 
Diabetes duration (years) n/a 9.83 ± 1.28 n/a 
MABP (mmHg) 100 ± 1.94 99.3 ± 4.13 0.822 
β-blockers 4/11 3/6 n/a 
ACE Inhibitors 4/11 5/6 n/a 
Ejection Fraction (%) 60.7 ± 2.07 57.9 ± 3.20 0.453 
E velocity (cm/s) 0.696 ± 0.0496 0.727 ± 0.0916 0.751 
A velocity (cm/s) 0.800 ± 0.108 1.08 ± 0.155 0.157 
E/A 0.999 ± 0.152 0.698 ± 0.0395 0.158 
 
3.2 Developed Force Measurements 
Figure 3.1 shows the developed force produced by diabetic and non-diabetic trabeculae 
throughout the experimental protocol. Diabetic trabeculae showed significantly lower 
developed force at baseline (D = 0.440 mN/mm2, ND = 1.53 mN/mm2, p = 0.0277), MTX (D 
= 0.486 mN/mm2, ND = 1.72 mN/mm2, p = 0.0313) and wash (D = 0.618 mN/mm2, ND = 1.72 
mN/mm2, p = 0.0352) phases. There was no significant difference between non-diabetic and 
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diabetic trabeculae with addition of MTX and KN93 (D = 0.595 mN/mm2, ND = 1.34 mN/mm2, 
p = 0.1336). The increase in developed force from addition of MTX to non-diabetic trabeculae 
was maintained in the wash phase of the protocol, with a decrease in developed force in non-
diabetic trabeculae only seen with addition of KN93 and MTX. 
 
Figure 3.1: Developed force of diabetic and non-diabetic trabeculae. Data presented as mean ± SEM. Statistical 
difference between diabetics (n=6) and non-diabetics (n=11) calculated with repeated measure two-way ANOVA 
with Geisser-Greenhouse correction and Sidak’s multiple comparisons test. *p < 0.05. 
Figure 3.2 shows fold-changes in developed force from baseline of diabetic and non-diabetic 
trabeculae samples. There were no significant differences between fold-changes in developed 
force between diabetic and non-diabetic samples during MTX (D = 1.47, ND = 1.20, p = 0.912), 
wash (D = 2.28, ND = 1.23, p = 0.505), or MTX + KN93 phases (D = 2.83, ND = 0.955, p = 
0.641), although diabetic samples trended towards a greater fold-change from baseline in all 
conditions when compared with non-diabetic samples. Non-diabetic samples showed similar 
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fold changes in developed force from baseline in both the MTX and wash phases, with a 
decreased fold-change when KN93 was added in conjunction with MTX. In contrast, fold-
changes in developed force of diabetic trabeculae consistently increased in each phase of the 
experiment. The increase in fold-change of developed force with addition of KN93 and MTX 
in diabetic samples is in stark contrast to the decrease in fold-change of developed force when 
KN93 and MTX is added to non-diabetic samples. 
 
Figure 3.2: Developed force fold-change of diabetic and non-diabetic trabeculae. Data presented as mean ± 
SEM. Statistical difference between diabetics (n=6) and non-diabetics (n=11) calculated with repeated measure 
two-way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple comparisons test. 
3.3 Max dF/dt Measurements 
Figure 3.3 shows max dF/dt fold change from baseline of non-diabetic and diabetic trabeculae. 
Both non-diabetic and diabetic tissue responded to MTX with a similar fold-change of max 
dF/dt from baseline, with no significant difference between diabetic and non-diabetic samples 
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(D = 1.07, ND = 1.04, p = 0.991). Diabetic samples trended towards a greater fold-change of 
max dF/dt from baseline compared to non-diabetic samples during the wash phase, although 
this difference was not significant (D = 1.16, ND = 1.06, p = 0.576). Addition of MTX + KN93 
to diabetic samples resulted in minimal fold-change of max dF/dt compared to the wash phase. 
Addition of MTX + KN93 to non-diabetic samples resulted in a decreased fold-change of max 
dF/dt compared to the wash phase. The difference of fold-change from baseline of max dF/dt 
between diabetic and non-diabetic tissue with addition of KN93 and MTX was not significant 
(D = 1.13, ND = 0.893, p = 0.352). 
 
Figure 3.3: Max dF/dt fold change of non-diabetic and diabetic trabeculae. Data presented as mean ± SEM. 
Statistical difference between diabetics (n=6) and non-diabetics (n=11) calculated with repeated measure two-
way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple comparisons test. 
3.4 Min dF/dt Measurements 
Figure 3.4 shows fold-change of min dF/dt from baseline of non-diabetic and diabetic 
trabeculae. Diabetic samples showed a decreased fold-change of min dF/dt from baseline 
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compared to non-diabetic trabeculae with addition of MTX, although this was not significant 
(D = 0.951, ND = 1.02, p = 0.629). No significant difference in fold-change of min dF/dt was 
seen between non-diabetic samples and diabetic samples during the wash phase of the 
experimental protocol (D = 0.982, ND = 1.02, p = 0.931). Minimal difference in fold-change 
of min dF/dt was seen with addition of MTX and KN93 to diabetic samples compared to the 
wash phase. Non-diabetic samples trended towards a decreased fold-change of min dF/dt with 
addition of KN93 and MTX compared to diabetic samples, although this was not significant (D 
= 0.982, ND = 0.887, p = 0.657). Non-diabetic samples also trended towards a decrease in fold-
change of min dF/dt with addition of KN93 and MTX compared to the wash phase of the 
experimental protocol. 
 
Figure 3.4: Min dF/dt fold change of non-diabetic and diabetic trabeculae. Data presented as mean ± SEM. 
Statistical difference between diabetics (n=6) and non-diabetics (n=11) calculated with repeated measure two-
way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple comparisons test. 
33 
3.5 Spontaneous Contractions 
Out of all the samples included in the final analysis, only one trabecula sample presented with 
spontaneous contractions. This sample showed spontaneous contractions from baseline 
throughout the entirety of the experiment. There was no observed change in the frequency of 
spontaneous contractions when adding either MTX or KN93 to the superfusate. The 
spontaneous contraction protocol seemed to hasten the degradation of muscle samples, so this 
protocol was not continued in further experiments to preserve the limited amount of human 
tissue available to this study. 
3.6 Control Experiments 
Addition of KN92 in place of KN93 to the superfusate had no significant effect on any of the 
contractile parameters in the control experiments (data not shown). Time control experiments 
with addition of KN93/KN92 to the superfusate before MTX addition were not significantly 
different from the other experiments (data not shown). 
3.7 Patient Matching Developed Force 
Figure 3.5 shows developed force produced by non-diabetic and diabetic samples, with patient 
matching based on relevant patient characteristics. Such characteristics included type of 
surgery, muscle CSA, patient age, gender and MABP levels. Trends between developed force 
produced between non-diabetic and diabetic samples are very similar to the developed force 
from all samples as shown in Figure 3.1, with decreased developed force at all phases of the 
experimental protocol in diabetic samples compared to non-diabetic samples. Differences 
between diabetic and non-diabetic samples at baseline (D = 0.440, ND = 1.44, p = 0.207), 
during MTX (D = 0.486, ND = 1.62, p = 0.294), wash (D = 0.618, ND = 1.61, p = 0.324) and 
MTX+KN93 phases (D = 0.595, ND = 1.29, p = 0.524) were not significant. 
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Figure 3.5: Developed force of patient matched non-diabetic and diabetic samples. Data presented as mean ± 
SEM. Statistical difference between diabetics (n=6) and non-diabetics (n=6) calculated with repeated measure 
two-way ANOVA with Geisser-Greenhouse correction and Sidak’s multiple comparisons test. 
3.8 Inotropic Response to Methoxamine 
Unexpectedly, some trabecula responded with a distinct negative inotropic response to addition 
of MTX. Samples were designated as positive responders (PR) if the developed force fold 
change from baseline in response to MTX was > 1, and negative responders (NR) if the 
developed force fold change from baseline in response to MTX was < 1. 
Figure 3.6 shows the fold-change in developed force of PRs and NRs to MTX throughout 
different phases of the experimental protocol. Both diabetic and non-diabetic tissue were 
present in either group. When perfusing the tissue samples with MTX, NRs had a significantly 
reduced fold-change in developed force from baseline (PRs = 1.54, NRs = 0.839, p = 0.0263) 
compared to PRs. There was no significant difference in the fold-change in developed force 
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between PRs and NRs to MTX in either the wash phase (PRs = 1.97, NRs = 0.932, p = 0.0791) 
or MTX + KN93 (PRs = 2.12, NRs = 0.700, p = 0.348) phase of the experimental protocol. The 
PRs trended towards an increased fold-change in developed force throughout each phase of the 
experimental protocol. NRs to MTX showed minimal fold-change in developed force 
throughout the experimental protocol. 36% of PRs were diabetic (4/11) and 33% of NRs were 
diabetic (2/6). 
 
Figure 3.6: Developed force fold-change of positive responders and negative responders to MTX 
administration. Data presented as mean ± SEM. Statistical difference between positive (n=11) and negative (n=6) 
responders calculated with repeated measure two-way ANOVA with Geisser-Greenhouse correction and Sidak’s 
multiple comparisons test. *p < 0.05. 
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3.8.1 Methoxamine Response and Diabetes 
Figure 3.7: Developed force fold-
change in response to MTX 
against HbA1C. Linear regression 
analysis, n = 17. 
Figure 3.7 shows the 
correlation between the fold-
change in developed force 
from baseline in response to 
MTX and patient HbA1C 
levels. No significant correlation between the two parameters was found with a linear regression 
analysis (p = 0.408, r2 = 0.0461). No difference was observed between diabetic patients with 
higher levels of HbA1C and non-diabetic patients with lower levels of HbA1C in their response 
to MTX. 
Figure 3.8: Developed force fold-
change in response to MTX against 
BMI. Linear regression analysis, n = 
17. 
Figure 3.8 shows fold-change in 
developed force from baseline in 
response to MTX of all patients 
graphed alongside measured 
BMI. No significant correlation 
between the two parameters was found with a linear regression analysis (p = 0.834, r2 = 
0.00303). No discernible difference is seen between the diabetic or non-diabetic patient groups. 
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Figure 3.9: Developed force fold-
change in response to MTX 
against diabetes duration. Linear 
regression analysis, n = 6. p* < 
0.05. 
Figure 3.9 shows fold-change 
in developed force from 
baseline in response to MTX 
of diabetic patients, graphed 
alongside diabetes duration. These two parameters showed a significant correlation with a linear 
regression analysis (p = 0.0352, r2 = 0.710). Patients with a diabetes duration greater than 10 
years trended towards a blunted inotropic response to MTX, with a fold-change in developed 
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This project aimed to examine the differences in contractile parameters and arrhythmogenesis 
in trabeculae from human right atrial appendage samples isolated from diabetic and non-
diabetic patients. I aimed to determine the role of CaMKII and the α-adrenergic system in the 
dysfunctions in contractility and arrhythmia commonly seen in diabetic patients. I aimed to 
examine these differences through superfusion of the trabeculae samples with MTX, an α-AR 
agonist, and KN93, an inhibitor of CaMKII. 
I hypothesised that the positive changes in contractile parameters with administration of MTX 
would be reduced to a greater extent in diabetic tissue compared to non-diabetic tissue and that 
administration of MTX would result in arrhythmogenesis in the tissue. I also hypothesised that 
CaMKII inhibition with KN93 would decrease contractility and arrhythmogenesis in diabetic 
tissue to a greater extent than non-diabetic tissue, due to overactive CaMKII in these diabetic 
samples. 
4.1 Basal Characteristics and Patient Matching 
Baseline characteristics of patients in the diabetic and non-diabetic patient groups were 
examined in Table 3.1, with the aim to detect any differences between the two groups and 
identify any potentially confounding variables. The only significant differences between the 
groups were found in BMI and HbA1C levels, both of which were significantly raised in the 
diabetic patients. Obesity is a common comorbidity of T2DM (American Diabetes Association, 
2014); thus, elevation of BMI levels in these patients was expected. HbA1C, a measure of 
glycated haemoglobin in the blood, allows for an estimation of blood glucose over a long term 
period (World Health Organisation, 2016). As T2DM patients often present with chronic 
hyperglycaemia, it was expected to see raised HbA1C levels in the diabetic patient group.  
Interestingly, despite HbA1C levels being significantly raised in diabetic patients, levels of 
blood glucose were raised, but not significantly different from non-diabetic patients. Only four 
out of eleven non-diabetic samples and three out of six diabetic samples had a blood glucose 
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measurement recorded in the patient database. This absence of data may have affected the 
variability of blood glucose in these patients, resulting in the insignificant difference observed 
between the two patient groups. 
Similarities of functional parameters such as ejection fraction, E velocity, A velocity and the 
E/A ratio between the two patient groups show that an underlying cardiac dysfunction distinct 
from diabetes is unlikely to be influencing the results in this study. Furthermore, upon patient 
matching diabetic and non-diabetic samples based on relevant patient characteristics as shown 
in Figure 3.5, similar trends are observed as in the whole sample data of Figure 3.1. The lack 
of significant differences between the diabetic and non-diabetic tissue in Figure 3.5 is likely 
due to the small sample size of six samples in each analysed group. This again suggests that 
underlying patient characteristics distinct from DM are not influencing the differences in 
developed force seen between the two patient groups. 
4.2 Developed Force Measurements 
As shown in Figure 3.1, diabetic tissue showed significantly reduced developed force at 
baseline, MTX and wash phases of the experimental protocol. Diabetic cardiac tissue is known 
to have impaired contractile function, despite normal ejection fraction (Levelt et al., 2016; 
Bening et al., 2018; Daniels et al., 2018). With addition of KN93 to the superfusate, non-
diabetic tissue showed a decrease in developed force. There was no significant difference 
between the diabetic and non-diabetic groups during the MTX+KN93 wash phase. This may 
be due to inhibition of CaMKII in non-diabetic samples resulting in a decrease in developed 
force, coming nearer to levels of developed force exhibited by the diabetic tissue. As shown in 
Figure 3.2, diabetic tissue responded with an increased fold-change in developed force with 
addition of KN93+MTX to the tissue which opposes my hypothesis. Daniels et al. (2018) 
observed a similar result when perfusing diabetic tissue with KN93, so CaMKII inhibition by 
KN93 may be rescuing the impaired contractility seen in diabetic samples. A similar rescue of 
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contractility with CaMKII inhibition has been seen in other disease states such as heart failure 
(Sossalla et al., 2010). This could also explain why no significant difference was seen in Figure 
3.1 during the MTX+KN93 phase between non-diabetic and diabetic tissue. Inhibition of 
CaMKII may be restoring contractility in the diabetic tissue nearer to non-diabetic levels of 
developed force. Both the diabetic and non-diabetic tissue responded in a very similar and 
minor manner to MTX administration as shown in Figure 3.2. Thus, it is unlikely that the MTX 
added in the MTX+KN93 phase of the experiment is contributing to the increase in developed 
force in diabetic tissue. 
The similar contractile response to MTX administration in both diabetic and non-diabetic tissue 
as shown in Figure 3.2 was unexpected and opposes my hypothesis. The finding that the 
contractile response to MTX was slightly, but not significantly, increased in diabetic tissue was 
also seen by Kamata et al. (1997) in diabetic rat isolated papillary muscle. During the wash 
phase of the experiment, diabetic tissue showed an unexpected increase in fold-change of 
developed force from baseline, compared to the MTX phase as shown in Figure 3.2. This 
contractile response may be due to the effects of MTX, with downstream effectors in the 
signalling pathway taking longer to reach their maximal inotropic effect than the 30 minute 
superfusion of MTX in this study. Yang and Endoh (1994) showed that MTX reaches its 
maximal PIE by 30 minutes in rabbit ventricular tissue, although their study did not examine 
the effect of diabetes on the time period of the MTX response. As no such delayed inotropic 
effect seems to be occurring in the non-diabetic tissue in Figure 3.2, it is plausible that diabetes 
or some other factor in the diabetic tissue is affecting the downstream signalling pathways 
involved in α-AR stimulation, affecting the time to maximal inotropic effect in the tissue. 
Figure 3.1 shows the non-diabetic tissue increasing in developed force with addition of MTX 
to the tissue. This increase in developed force is maintained during the wash phase of the 
experiment, with developed force only returning to near baseline levels with addition of KN93 
during the MTX+KN93 phase of the experimental protocol. This suggests that MTX 
42 
superfusion is resulting in autonomous activation of CaMKII within the tissue, as this inotropic 
effect is preserved even with washing MTX out of the tissue superfusate, the inotropic effect 
only attenuated with inhibition of CaMKII. The complete attenuation of the PIE from MTX 
administration with both KN93+MTX superfusion highlights the importance of CaMKII in the 
downstream effects from α-AR stimulation. This is the first study to implicate the involvement 
of CaMKII in the α-adrenergic cascade in human tissue samples, which builds on previous work 
by Khan (2019) implicating CaMKII in the α-adrenergic cascade in mouse models. 
4.3 Maximum and Minimum dF/dt Measurements 
Both diabetic and non-diabetic tissue showed minimal fold-changes in both min dF/dt and max 
dF/dt throughout the experimental protocol as shown in Figure 3.3 and Figure 3.4. Interestingly, 
despite diabetic tissue showing an increase in max dF/dt compared to non-diabetics with MTX 
superfusion in Figure 3.3, diabetic tissue shows a decrease in min dF/dt compared to non-
diabetics with MTX superfusion in Figure 3.4. This is in partial contrast to findings by Heyliger 
et al. (1982), who observed blunted increases in both max and min dF/dt in response to MTX 
administration in diabetic tissue compared to non-diabetic tissue. Wald et al. (1988) showed 
significantly heightened increases in max dF/dt with superfusion of MTX in diabetic rat 
ventricular tissue, which is in contrast with this study. It should be noted that Wald et al. (1988) 
examined acute diabetic rats, with tissue isolated from the animals only 3 days following 
experimental induction of diabetes. Diabetic patients included in this study had diabetes on 
average for 9.83 ± 1.28 years as shown in Table 3.1, with no patient having had diabetes for 
less than 4 years. Chronic diabetes is known to result in reduced inotropic responses in human 
atrial appendage (Guner et al., 2004), so it is plausible that the long mean duration of diabetes 
in this study is contributing to the different findings between this project and other studies. 
Diabetic patients showed a decrease in min dF/dt across both the MTX and wash phases of the 
experimental protocol compared to non-diabetic patients as shown in Figure 3.4, although this 
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difference was not significant. Lamberts et al. (2014) noted impaired relaxation in human 
trabeculae from patients with T2DM, although the difference seen in their study was much more 
substantial. Notably, Lamberts et al. (2014) only included patients undergoing CABG surgeries, 
whereas this project included patients undergoing a variety of valve replacements alongside 
CABG patients. 
Daniels et al. (2018) showed that diabetic rat trabeculae exhibited blunted rates of both 
contraction and relaxation, which were partially rescued with KN93 superfusion. As the 
diabetic trabeculae studied in this project showed no impairment of either contraction or 
relaxation, superfusion with KN93 had minimal effect on either of these parameters. This 
contrasts with the rescue of developed force seen in diabetic trabeculae with KN93 superfusion, 
as shown in Figure 3.1. 
4.4 Spontaneous contractions 
Only one sample included in the final analysis showed evidence of spontaneous contractions 
throughout the experimental protocol. Out of all patients included in the final analysis, eight 
out of seventeen showed evidence of atrial fibrillation either before or after the operation. The 
interactions between α-ARs and atrial fibrillation are poorly understood, so further studies may 
be required to elucidate whether this may have affected this projects results. There was no 
change in the frequency of spontaneous contractions with addition of either MTX or KN93 to 
the superfusate. This was unexpected considering my previous hypothesis, that inhomogeneity 
of atrial conduction as seen in diabetics by Senges et al. (1980), may lead to arrhythmia through 
heterogeneous activation of α1-ARs as described by Kurz et al. (1991). Previous studies have 
shown that arrhythmogenic effects from α-AR stimulation only occur in ischaemic tissue 
(Sheridan et al., 1980; Sheridan & Culling, 1985; Culling et al., 1987) and that the function of 
α-ARs is maintained, or even heightened, in ischaemia (Corr et al., 1981; Itaya et al., 1990; 
Litwin et al., 1995). The use of the α-AR antagonist phentolamine has been shown to produce 
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anti-arrhythmic effects when administered to human patients (Gould et al., 1971). Inhibition of 
CaMKII by KN93 administration has been shown in various disease states to reduce arrhythmia 
(Ma et al., 2012; Erickson et al., 2013; Feng et al., 2017). As the frequency of spontaneous 
contractions was unchanged with addition of KN93, this suggests that the spontaneous 
contractions observed in the tissue sample were not primarily mediated by CaMKII. 
The experimental protocol used in this study for measuring arrhythmia focused on spontaneous 
contractions as a measure for arrhythmogenesis in the trabeculae. This may have been a limiting 
factor in measuring arrhythmia, as we were only able to measure any arrhythmogenic events in 
terms of the contractile events they may produce. Smaller arrhythmic events occurring on a 
cellular level were unable to be measured with the experimental setup, which may have been 
occurring with administration of MTX to the tissue samples. 
4.5 Methoxamine Contractile Response 
Unexpectedly, several of the tissue samples showed either a minimal, or negative inotropic 
response to MTX administration. As shown in Figure 3.6, samples in the NR group showed a 
significantly reduced fold-change in developed force with superfusion of MTX, compared to 
PRs. The PR group showed steady increases in developed force across the experimental 
protocol, in contrast to NRs which instead showed minimal changes in developed force 
throughout the experiments. Various studies have shown a NIE in response to α-AR stimulation 
(Imai, 1961; Skomedal et al., 1982; Tanaka et al., 1995), some suggesting that the similarity of 
the chemical structures of MTX and epinephrine result in an antagonistic effect of MTX on 
epinephrine, leading to the NIE (Imai et al., 1961). Overexpression of α1B-ARs may depress the 
β-adrenergic response due to overactivation of Gi (Woodcock, 2007). Gould et al. (1969) 
showed a PIE when inhibiting α-ARs in human subjects, suggesting that this increase in 
contractility is due to α-AR antagonism leading to an increased production of catecholamines. 
Kamata et al. (2006) also noted a NIE in response to MTX at intermediate concentrations of 
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the drug (around 10-6 M) which returned to a PIE with higher concentrations in isolated rat 
papillary muscle. Interestingly, this transient NIE seems to disappear in 10-week diabetic rats, 
but not in shorter duration diabetic rats (Kamata et al., 2006), suggesting that the duration of 
diabetes is affecting the NIE in response to MTX. 
4.5.1 Effects of Diabetes 
The finding that PRs showed a slight increase in developed force with addition of KN93 is akin 
to the contractile trend seen in diabetic tissue, so an obvious next step was to examine the 
proportion of diabetics in the negative and positive responding groups. Interestingly, both 
groups showed very similar proportions of diabetics, with 36% of PRs diabetic (4/11) and 33% 
of NRs diabetic (2/6). As shown in Figure 3.7, minimal correlation is seen between the 
developed force response to MTX administration and levels of HbA1C in patients. This 
suggests that the severity of hyperglycaemia is not affecting the contractile response to MTX. 
It may be argued that adequate glycaemic control in the diabetic patients is impacting this, as 
all diabetic patients included in this study were medicated with metformin. Despite this, Table 
3.1 clearly shows significantly raised HbA1C levels in diabetic patients. 
Previous studies have suggested that vascular α-AR sensitivity is heightened in T2DM and 
obesity (Naik et al., 2006; Bussey et al., 2014), with Bussey et al. (2014) suggesting that α-AR 
sensitivity is primarily affected by obesity rather than DM. The present study found minimal 
correlation between patient BMI levels and the developed force fold-change in response to 
MTX administration as shown in Figure 3.8. Despite this, BMI levels were seen to be 
significantly elevated in diabetic patients, as shown in Table 3.1. Both Naik et al. (2006) and 
Bussey et al. (2014) studied this effect in rat models, which could account for the differences 
in findings in the present study. Cardiac or vascular specific changes to α-ARs may also be 
occurring in both cases, differentially affecting the subsets of α-ARs in obesity. 
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Interestingly, upon examining the correlation between DM duration and the developed force 
response to MTX, a strong correlation is visible as shown in Figure 3.9. This suggests that the 
duration of DM is key in determining the contractile response to MTX. Denervation occurring 
in chronic DM may be leading to downregulation of the α-ARs, as seen in previous studies 
(Heyliger et al., 1982; Williams et al., 1983; Latifpour & McNeill, 1984; Tanaka et al., 1992). 
This finding is in stark contrast to the findings of Kamata et al. (2006) as previously discussed, 
which showed an increased sensitivity to MTX at 10-weeks of diabetes in rat models. The 
observed negative correlation between the developed force response to MTX and diabetes 
duration does seem to be heavily influenced by one diabetic sample, which exhibited a fold-
change of ~3.5 from baseline and was the only diabetic sample included in the final analysis 
with a duration of diabetes below 10 years. This makes it difficult to draw strong conclusions 
from the observed correlation, without more contractile data from diabetics with differing 
durations of the disease. Although DM may be impacting the contractile response to MTX, this 
leaves open the explanation for why several non-diabetic samples were found in both the 
positive and negative responding groups. 
4.5.2 Non-Diabetic Response 
The response to α-AR stimulation has been examined in detail in terms of its interactions within 
an ischaemic environment. Increases in cardiac α-ARs have been observed in a short time 
period following an ischaemic event (Corr et al., 1981), along with increased numbers of these 
receptors outside the ischaemic area (Itaya et al., 1990). Ischaemia is also known to increase 
the responsiveness of the α-ARs in terms of their contractile response (Kurz et al., 1991) and 
as previously discussed, their involvement in arrhythmogenesis (Sheridan & Culling, 1985). 
Furthermore, α-ARs are known to maintain their density and inotropic response in heart failure, 
remaining functional in the myocardium (Litwin et al., 1995; Janssen et al., 2018). The positive 
responders to MTX seen in Figure 3.6 may have a greater proportion of ischaemic tissue, 
sensitising the trabeculae samples to MTX administration and resulting in the PIE seen in the 
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present study. Culling et al. (1987) noted that MTX superfusion had minimal effects on 
arrhythmogenesis in normal myocardium, with others noting the minor inotropic effects that α-
AR stimulation has in healthy tissue compared to β-adrenergic receptor stimulation (Jakob et 
al., 1988). This may explain the minimal response to MTX superfusion seen in several of the 
patient samples. 
Wang et al. (2009) showed a switch to a positive inotropic response from a negative inotropic 
response to α-AR stimulation, following heart failure in mouse right ventricular tissue. 
Interestingly, hearts subjected to small infarcts did not show such a change in the inotropic 
response, suggesting an injury threshold plays a part in this altered response (Wang et al., 2009). 
As such an infarct would result in portions of the myocardium becoming ischaemic and 
considering the large body of evidence implicating ischaemia in α-AR responsiveness, it is 
feasible to assume the proportion of ischaemic tissue is playing a role in the findings from Wang 
et al. (2009). However, no such inotropic change was observed in left ventricular tissue 
following heart failure (Wang et al., 2009), suggesting differences in chamber function of the 
α-ARs. Conversely, Janssen et al. (2018) observed no such changes in the inotropic effect of α-
ARs following heart failure in both left and right ventricular tissue from human patients. This 
suggests that heart failure and ischaemia may not alter the effects of α-AR stimulation in human 
models. More work should be performed to confirm this finding and examine the inotropic 
effect of α-ARs in ischaemic tissue without heart failure. 
An alternative hypothesis to explain the NIE in response to MTX involves the observed 
negative inotropic response to high concentrations of α-AR agonists (Imai et al., 1961; Tanaka 
et al., 1995). If cardiac tissue is sensitised to the effects of such an α-AR agonist in situations 
of ischaemia, an α-AR agonist may cause a NIE in more ischaemic tissue, as opposed to a PIE 
seen in healthy, non-ischaemic myocardium. Such an effect may have occurred in the current 
study, leading to a distinct NIE in response to MTX administration in more ischaemic 
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trabeculae samples. However, this hypothesis is conflicting with data from Kamata et al. (2006) 
showing a PIE with high concentrations of MTX. 
4.5.3 CaMKII and Positive Responders to MTX 
As shown in Figure 3.6, the PR group showed an increased fold-change in developed force 
during superfusion of both MTX+KN93. This contrasts with the NRs, which instead showed a 
decreased fold-change in developed force with superfusion of MTX+KN93. This increase in 
developed force with addition of KN93 suggests that inhibition of CaMKII is rescuing 
contractility in the PR tissue samples. As shown in Figure 3.2, this is a similar pattern to when 
diabetic samples are superfused with both MTX and KN93, which Daniels et al. (2018) also 
noted when inhibiting CaMKII in diabetic trabeculae. If ischaemia is playing a role in the 
inotropic response to MTX administration, this may be impacting downstream targets of the α-
AR cascade such as CaMKII. Levels of oxidative stress are well known to be heightened in 
myocardial ischaemia (Ferrari et al., 2004) and oxidative stress is known to activate CaMKII 
(Erickson et al., 2008). This oxidised form of CaMKII has been linked to impaired cardiac 
function, so inhibition of the oxidised enzyme may produce similar increases in cardiac 
contractility as seen in Daniels et al. (2018) and the current study when inhibiting CaMKII in 
diabetic patients. However, the high variability seen in Figure 3.6 when perfusing PRs with 
both MTX+KN93 suggests that some samples in the PR group may have had disproportionate 
changes in developed force with KN93 superfusion. Further studies regarding the level of 
ischaemia in the trabeculae samples and their inotropic response to MTX will need to be carried 
out to test this hypothesis. 
4.6 Limitations 
There are several limitations of the current study, which could be ameliorated for future 
research projects. As previously mentioned, the lack of arrhythmogenesis seen in the tissue 
samples was unexpected, with previous literature implicating both the α-ARs and CaMKII in 
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arrhythmogenesis. The protocol for measuring arrhythmogenesis in trabeculae samples looked 
for the presence of spontaneous contractions as a measure for arrhythmia. As this experimental 
setup is only able to measure arrhythmia in terms of the contractile response arising from 
arrhythmogenic events, we were unable to detect any alterations in the tissue that may not have 
resulted in a contractile event. Addition of MTX or KN93 to the samples may have affected the 
frequency of calcium sparks, without leading to a contractile event. Future studies may wish to 
elucidate the arrhythmogenic effects of MTX and KN93 with more sensitive measures of 
arrhythmia, such as measurements of calcium sparks in isolated cardiomyocytes. 
Due to the source of the tissue used in this study, many patients presented with pre-existing 
conditions and pathologies, such as coronary artery disease and valve regurgitation. Attempts 
were made to correct for this by examining relevant patient characteristics as shown in Table 
3.1. However, the non-diabetic control cannot be considered as healthy cardiac tissue, and as 
such has the potential to influence the results due to any underlying confounding pathology in 
the trabeculae samples. 
Although Janssen et al. (2018) noted no chamber differences between left and right ventricular 
human trabeculae in response to α1A-AR stimulation, chamber differences may persist between 
ventricular tissue and the atrial tissue used in this study. Given the functional differences 
between atrial and ventricular tissue, it is plausible that expression of α-ARs may differ between 
the two chambers. Future studies may wish to examine any difference in α-AR responsiveness 
between ventricular and atrial trabeculae, for greater knowledge on any changes in expression 
during disease states such as DM. 
Non CaMKII specific effects of KN93 and KN92 have been examined in previous studies, 
showing off-target effects on L-type calcium channels (Gao et al., 2006). Despite these off-
target effects of KN93 and KN92, previous experiments in our laboratory have shown a 
completely attenuated contractile response to MTX in CaMKII knockout mouse models (Khan, 
2019), suggesting that CaMKII inhibition by KN93 is the causal factor for the decreased 
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contractility seen in Figure 3.1 in non-diabetic tissues. Another CaMKII inhibitor such as AIP 
used in Daniels et al. (2018), may be useful in future studies to elucidate any influence of off-
target effects of KN93 and KN92 on the results from this project. 
4.7 Clinical Implications 
The proposed implication of CaMKII in the α-AR cascade in human tissue may contraindicate 
the use of α-AR agonists in certain patients, such as those in which activation of CaMKII would 
have significant detrimental effects. As CaMKII is characterised as pathologically 
overactivated in disease states such as myocardial infarction (Erickson et al., 2008; Luo et al., 
2013), DM (Erickson et al., 2013; Daniels et al., 2018) and HF (Sossalla et al., 2010), the use 
of α-AR agonists in these conditions may be detrimental to cardiac health. 
Previous studies have implicated α-AR antagonism in reducing the prevalence of both 
arrhythmia and the rescue of contractility in disease states (Gould et al., 1969; Gould et al., 
1971). However, as this project showed minimal difference in responses to MTX administration 
between diabetic and non-diabetic patients, it remains unclear whether α-AR antagonism could 
be used therapeutically in DM. Studies have shown the beneficial effects of α-ARs in rescuing 
cardiac function and cell death, with suggestions that the receptors may be involved in β-AR 
responsiveness (O'Connell et al., 2006; Huang et al., 2007). McCloskey et al. (2003) showed 
that these protective effects are only lost in knockout models, not with acute inhibition of the 
α-ARs with prazosin. This does suggest that chronic treatment with an α-AR antagonist may 
have detrimental cardiac effects in patients, although this is yet to be fully elucidated. 
The finding that inhibition of CaMKII in diabetic tissue rescued cardiac contractility supports 
previous findings by Daniels et al. (2018). Therapeutic CaMKII inhibition in diabetic patients 
presents as a clinical possibility, as it may rescue the impaired contractility commonly seen in 
these patients (Levelt et al., 2016; Bening et al., 2018; Daniels et al., 2018). Studies to develop 
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a clinically suitable inhibitor of CaMKII should be considered in order to minimise the 
substantial impact that heart disease has on patients suffering from T2DM. 
4.8 Future Directions 
As this project obtained limited data on the contractile response to MTX of diabetics with a 
duration of disease less than 10 years, future studies may wish to examine the changes in the 
MTX contractile response with diabetics of a shorter duration. This could include immunoblot 
studies to determine the expression of α-ARs in tissue samples, examining the relationship 
between receptor density, duration of DM and the MTX contractile response. As previously 
discussed, current literature shows conflict as to the changes in α-AR density in DM, with 
conflict also persisting as to the changes in receptor density in the vasculature (Schulingkamp 
et al., 2005; Ruggeri et al., 2006). Ruggeri et al. (2006) suggests that changes in α-AR 
sensitivity in DM may not involve an alteration in receptor number, but instead a change in 
downstream signalling pathways. Future studies could examine alterations in the downstream 
α-AR signalling pathway in DM. 
With evidence from the current study and Khan (2019) implicating CaMKII in the α-AR 
inotropic response, the exact mechanism by which CaMKII is activated by this pathway remains 
to be elucidated. Stimulation of α1-ARs is known to increase intracellular calcium via 
phosphoinositol hydrolysis (Motulsky & Insel, 1982), with high levels of intracellular Ca2+ 
necessary to activate CaMKII (Rosenberg et al., 2005). Future projects may experimentally 
inhibit downstream targets of the α-AR signalling cascade such as phosphoinositol breakdown, 
to determine their impact on CaMKII activation. 
Considering the literature implicating the role of ischaemia in the MTX contractile response, it 
could be intriguing to examine the effects of inducing acute ischaemia in trabeculae samples 
and observing any changes to the contractile response to MTX. Corr et al. (1981) showed a 
detectable increase in cardiac α-ARs only 30 minutes following ischaemia in feline models. 
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Such an effect could be studied in human tissue via immunoblot methods, along with any 
changes in contractile response with the trabeculae setup used in the present study. A measure 
of quantifying ischaemia in samples could also be employed either on trabeculae samples, or 
by applying a quantitative score of ischaemia to patient tissue following surgical removal of the 
RAA. 
4.9 Conclusion 
To my knowledge, this project is the first to implicate the role of CaMKII in the α-AR cascade 
in human cardiac tissue. I showed that the contractile response to MTX was not significantly 
different between diabetic and non-diabetic human cardiac tissue samples, suggesting that some 
other factor such as myocardial ischaemia is resulting in the differential inotropic responses to 
MTX administration. Limitations in measurements of arrhythmogenesis may have impacted the 
lack of recorded arrhythmia in the present study, with more sensitive measures of arrhythmia 
required to investigate this in the future. With the data gathered in this project, I was unable to 
support either of my hypotheses. The experiments showed rescued contractility in diabetics 
with pharmacological inhibition of CaMKII, lending support to the notion of CaMKII inhibition 
being a viable therapeutic treatment. I have outlined various future directions of research, which 
may aid in understanding the impact of diabetes or other disease states on the multifaceted 
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